Unraveling complexity. Harnessing insights.

Investor Relations

Corporate Overview

Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biotechnology company focused on the development of targeted therapies for a number of different cancers. Our mission is to extend the lives of cancer patients by developing potential first-in-class therapies and companion diagnostics.

Celcuity’s lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is conducting a Phase 3 registration-enabling clinical trial to evaluate gedatolisib in patients with HR+/HER2- advanced breast cancer. Our CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies.

Data Provided by Quotemedia with delay

STOCK
INFORMATION

NASDAQ: CELC

Press Releases

Upcoming Events

There are currently no events to display.

Date

Event Title

There are currently no upcoming events.

Wednesday, August 14, 2024 at 4:30 p.m. ET

Celcuity Second Quarter 2024 Financial Results Conference Call

Monday, November 13, 2023 at 8:00 a.m. ET

Celcuity Third Quarter 2023 Financial Results Conference Call

Date

Event Title

Thursday, September 21, 2023
10:00 a.m. – 12:00 p.m. ET

Virtual Science Day for Investors

Date & Time

Event Title

June 9, 2023 at 12:15 pm ET

Jefferies Healthcare Conference

May 31, 2023

20th Annual Craig-Hallum Institutional Investor Conference

March 23, 2023 at 4:30 PM ET

Celcuity Fourth Quarter and Full Year 2022 Financial Results Webcast/Conference Call

November 17, 2022

13th Annual Craig-Hallum Alpha Select Conference

August 7 – 8, 2023

BTIG Virtual Biotechnology Conference 2023

Thursday, August 10, 2023 at 4:30 PM ET

Celcuity Second Quarter 2023 Financial Results Conference Call

June 9, 2022 at 2:30 PM ET

Jefferies Healthcare Conference

May 16, 2022 at 4:30 PM ET

Celcuity First Quarter 2022 Financial Results Webcast/Conference Call

March 23, 2022 at 4:30 PM ET

Celcuity Fourth Quarter and Full Year 2021 Financial Results Conference Call